🚨 COME JOIN OUR TEAM!!! My lab is looking for a talented postdoc to join our ranks at the Department of Biomedicine of the University of Basel 🇨🇭! If you are a T-cell enthusiast fascinated by exhaustion and cancer immunotherapy - Apply here 👇 👇 👇
jobs.unibas.ch/offene-stellen…

Safety and anti-tumor activity of autologous Her2 CART in sarcoma. Congratulations Nabil, Meena and the extended team Center for Cell and Gene Therapy and beyond
nature.com/articles/s4301…

Celebrating some lab wins with the team 💪🏻💪🏻

Excited to share that our paper is now out in Nature Communications! We explore how CAR affinity influences CAR-T cell sensitivity to PD1/PD-L1 inhibition. Huge congrats to Irene Andreu and Alba Rodríguez for their exceptional work! IDIBAPS Hospital Clínic
doi.org/10.1038/s41467…

Super excited to see the exa-cel (Casgevy) #SickleCellDisease results out today in NEJM. These are the data that led to FDA approval Dec23 (during #ash2023 ). Terrific study steering committee. More data to come in younger pts. Now to work on access! Vertex Pharmaceuticals Cancer Center @ CHOP

Two exciting studies out in nature show that high tumor PGE2 limits IL-2 sensing and antitumor function in TIL. Disrupting this axis can potently enhance antitumor responses. Nice work George Coukos Jan P. Böttcher and teams!

nature.com/articles/s4158…

nature.com/articles/s4158…

🚨We are hiring a Research Assistant to help us supercharge CAR T cells!

Candidates of all experience levels are encouraged to apply. Some lab experience is required, mouse experience is preferred. 2-year minimum commitment.

Please retweet!

Apply here: chop.wd5.myworkdayjobs.com/CHOPExternalCa…

Spring in Philly is different

Love this new review from Nicholas P. Restifo and Luca Gattinoni on engineering synthetic T cell states for T cell based immunotherapies.

rupress.org/jem/article/22…

Not all heroes wear capes 🙌🏻

One big hurdle in CAR T-cell #immunotherapy is the short-lived effectiveness. But now, supported in part by St. Baldrick’s, researchers have discovered that a certain protein could be the secret to boosting CAR T-cells' staying power. Learn more: ow.ly/uBAv50RgKjV

Researchers from CHOP and Stanford Medicine have discovered that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers. ms.spr.ly/6017ch2ct

In a study supported by #PIDDN , Alex Doan, Kat Mueller, PhD, Andy Chen, Mackall Lab, Evan Weber, et al. showed that overexpressing FOXO1 increases the antitumor activity of #CARTcells in preclinical models nature nature.com/articles/s4158….

Nature research paper: FOXO1 is a master regulator of memory programming in CAR T cells go.nature.com/4aNnPD8

PICI-supported nature study: 2022 Parker Bridge Fellow Evan Weber & Penn Medicine, Children's Hospital Stanford Medicine program CAR T cells w/ high FOXO1. Gives stem-cell properties, faster growth & longer survival. Could improve CAR T efficacy across cancers. nature.com/articles/s4158…

Grateful to Sara Reardon for the fantastic write-up of our FOXO1 study and the companion study from the Darcy/Junyun Lai/A/Prof Paul Beavis team.

I'm wildly proud to share our FIRST Weber Lab paper, out today in nature! I want to share a story about how this whirlwind of a project came together. A 🧵 on teamwork, open science, and how far we can go when we intentionally build a culture of trust in research. 1/

The story behind the story! Collaboration and team science for the win.

Bioengineered immune cells have been shown to attack and even cure cancer, but they tend to get exhausted if the fight goes on for a long time.

Now, two separate research teams have found a way to rejuvenate these cells: make them more like stem cells. go.nature.com/3vBfcwA